Sucampo Pharma (SCMP) Tops Q2 EPS by 1c; Reiterates 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
Sucampo Reports Second Quarter 2017 Financial Results
August 2, 2017 6:30 AM EDTPatent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1
Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse Inc. Acquisition; EPS were $0.28 on an Adjusted Diluted Basis Excluding IP R&D Charge and Other Adjustments*
CPP-1X/Sulindac Phase 3 Trial for the Treatment of Familial Adenomatous Polyposis Continues After Planned Interim Futility Analysis
Company Reiterates 2017 Guidance
Company to Host Conference... More
